Beacon Therapeutics has secured more than $75 million in Series C financing to advance the development and commercial readiness of its lead ocular gene therapy candidate. The funding will support late-stage clinical programmes targeting inherited retinal diseases with limited treatment options.
Beacon Therapeutics Series C financing led by Goldman Sachs Alternatives
The oversubscribed financing round was led by Life Sciences at Goldman Sachs Alternatives, with participation from the Retinal Degeneration Fund. Existing investors including Syncona, Forbion, Oxford Science Enterprises and Advent Life Sciences also contributed.
Beacon Therapeutics is a clinical-stage biotechnology company focused on gene therapies for rare and prevalent ocular diseases. The new investment strengthens its balance sheet as it prepares for key clinical milestones.
Funding to advance laru-zova for X-linked retinitis pigmentosa
Importantly, the capital will be used to complete development of laru-zova, a gene therapy currently under investigation for X-linked retinitis pigmentosa (XLRP). Pivotal data from the VISTA trial are expected in the second half of 2026.
In addition, Beacon plans to accelerate commercial preparations for laru-zova while progressing earlier-stage programmes. These include candidates targeting geographic atrophy and inherited cone rod dystrophy.
Board appointment strengthens investment oversight
As part of the financing, Colin Walsh, Managing Director in Life Sciences at Goldman Sachs Alternatives, has joined Beacon Therapeutics’ board of directors. The appointment reflects increased investor involvement as the company approaches late-stage development.
Meanwhile, the Retinal Degeneration Fund highlighted the unmet medical need in XLRP, where no approved disease-modifying treatments are currently available.
Upcoming industry presentation
Beacon Therapeutics will present at the 44th Annual JP Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 13 January 2026.
Further information about the company is available on the Beacon Therapeutics website. Additional details on the lead investor can be found at Goldman Sachs.
Related coverage is available in the Life Sciences Global News Biotechnology section.
